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Subclinical gut inflammation occurring in patients affected by spondyloarthritis (SpA) 
is correlated with the severity of spine inflammation. Several evidences indicate that 
dysbiosis occurs in SpA, and that may modulate intestinal permeability and intesti-
nal immune responses. The presence of intestinal dysbiosis is accompanied in SpA 
patients with the presence of zonulin-dependent alterations of gut-epithelial and 
gut-vascular barriers. The leakage of epithelial and endothelial surface layers is followed 
by the translocation of bacterial products, such as lipopolysaccharide and intestinal 
fatty acid binding protein, in the systemic circulation. These bacterial products may 
downregulate the expression of CD14 on circulating monocytes leading to an “anergic” 
phenotype. In the gut, IL-23 may induce the expansion of innate immune cells such as 
mucosal-associated invariant T cells, γδ T cells, and innate lymphoid cells of group 3 
that through the interaction with MAdCAM1 may recirculate form the gut to the sites 
of SpA active inflammation. On the basis of these findings, gut inflammation observed 
in SpA patient seems to be not only an epiphenomenon of the on going systemic 
inflammatory process but may also represent the base camp in which inflammatory 
cells are activated and from whom they shuttle.
Keywords: spondylitis, gut microbiome, inflammation mediators, innate immune response, enthesitis-related 
arthritis
inTRODUCTiOn
Subclinical intestinal inflammation occurs in a significant number of patients affected by spondy-
loarthritis (SpA) and is correlated with the severity of spine inflammation (1, 2). Different studies 
indicate the occurrence of an altered microbiome (so-called dysbiosis) in the intestine of patients 
with SpA, associated with profound alterations of both gut-vascular barrier (GVB) and gut-epithelial 
barrier (Figure 1). The interaction between intestinal bacteria and the gastrointestinal immune 
system might drive in SpA the aberrant activation of innate immune cells that seem to be able to 
recirculate from the gut to the sites of SpA extraintestinal inflammation (Figure 1). On the basis of 
these findings, gut inflammation observed in SpA patient seems to be not only an epiphenomenon 
of the on going systemic inflammatory process but may also represent the base camp in which 
inflammatory cells are activated and from whom they shuttle (Figure 1). In this review, we will 
talk only about subclinical gut inflammation and SpA. The problem of the occurrence of clinically 
evident gut inflammation in SpA patients is more complex. Theoretically, we should consider such 
a patient as concomitantly affected by inflammatory bowel disease (IBD) and spondylitis. Our 
preliminary studies demonstrate that this kind of intestinal inflammation is immunologically more 
FiGURe 1 | Role of the gut inflammation in the pathogenesis of ankylosing spondylitis. Dysbiosis, occurring in the gut of AS patients, activates Paneth cells to 
produce antimicrobial peptides and possibly modulates the production of IL-23. Dysbiosis is also associated with zonulin-dependent alteration of both gut-epithelial 
barrier and gut-vascular barrier. The presence of altered epithelial and endothelial permeability is followed by the translocation in the systemic circulation of bacterial 
products such as lipopolysaccharide (LPS) and intestinal fatty acid binding protein (iFABP). These bacterial products may downregulate the expression of CD14 on 
circulating monocytes leading to an “anergic” phenotype. In the gut, IL-23 may induce the expansion of innate immune cells such as mucosal-associated invariant  
T (MAIT) cells, gd T cells, and innate lymphoid cells of group 3 (ILC3) that through the interaction with MAdCAM1 may recirculate form the gut to the sites of AS 
active inflammation.
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similar to Crohn’s disease (CD) than subclinical gut inflamma-
tion and requires more studies to be defined.
THe HiSTOPATHOLOGY OF SUBCLiniCAL 
inTeSTinAL inFLAMMATiOn in SpA
Two main histologic varieties of subclinical intestinal inflam-
mation have been described in the gut of SpA patients, the acute 
and the chronic type of inflammation (1). Acute inflammation 
is histologically similar to bacterial enterocolitis, characterized 
by the lamina propria infiltration with polymorphonuclear 
cells (1). The chronic type of inflammation, resembling CD is 
characterized by crypts distortion with villous atrophy, flatten-
ing and fusion of villi, increased infiltration of lamina propria 
mononuclear cells (LPMCs) and lamina propria lymphoid fol-
licles (1). More recently, our group has demonstrated the occur-
rence of specific histologic changes in SpA gut independently by 
the degree of intestinal inflammation. These alterations include 
goblet cells hyperplasia and increased mucins production and 
activation of Paneth cells (3). The natural history of subclinical 
gut inflammation in SpA in not clear even though it has been 
demonstrated that up to 10% of those patients displaying chronic 
gut inflammation will develop over the time a clinically overt 
CD (4). Further studies are required to clarify whether acute 
and chronic forms are a continuous histologic spectrum of the 
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same disease and/or a transition from one form to another may 
occur.
DYSBiOSiS in SpA GUT
The microorganisms that colonize the human body are col-
lectively termed the microbiome (5). The compositional and 
functional alteration in the microbiome, driven by a set of envi-
ronmental- and host-related factors, is defined as dysbiosis (5). 
Several evidences indicate that dysbiosis occurs in SpA. HLA-
B27 is one of the most important genetic risk factor for patients 
with SpA and the role of HLA-B27 in modulating the intestinal 
microbiome has been recently studied by the Rosenbaum’s 
group (6). The authors demonstrated that that Lewis rats 
transgenic for HLA-B27 and human β2-microglobulin had 
significant differences in the cecal microbiota compared with 
wild-type Lewis rats (6). Ciccia et  al. (3) demonstrated that 
both adherent and invading Gram+ and Gram− bacteria are 
observable in the inflamed ileum of SpA patients and are 
always associated with histological alterations characterized by 
the epithelial cell detachment, forming subepithelial vacuoles, 
and the presence of lamina propria edema with red blood cells 
extravasation.
Costello et  al. (7) performed bacterial community pro-
filing of terminal ileum biopsies of SpA patients. Ileal 
micro biome of patients with SpA differed was significantly 
different from healthy controls, with higher representation of 
Lachnospiraceae, Veillonellaceae, Porphyromonadaceae, and 
Bacteroidaceae and reduction of Prevotellaceae, Gemellaceae, 
Streptococcaceae, and Actinomycetaceae. A quantitative 
metagenomics study has been recently performed, based on 
shotgun sequencing of gut microbial DNA obtained from 
211 Chinese patients (8). SpA patients showed a significant 
increased abundance of Prevotella melaninogenica, Prevotella 
copri, and Prevotella sp. C561 and decreased representation 
of Bacteroides spp. Interestingly, the Bifidobacterium genus, 
commonly used in probiotics, was observed to accumulate 
in the SpA patients. 16S ribosomal RNA gene sequencing has 
been recently also performed on fecal DNA isolated from stool 
samples in SpA by Breban et al. (9). The authors evidenced that 
a disease-specific dysbiosis was present in SpA. The most strik-
ing change was a twofold to threefold increased abundance of 
Ruminococcus gnavus in SpA, as compared with both RA and 
HCs that was significantly correlated with the disease activity 
only in patients with a history of IBD. It is noteworthy that 
among healthy controls, significant difference in microbiota 
composition was also detected between HLA-B27+ and HLA-
B27− siblings, indicating that the genetic background may 
influence the microbiota composition. Tito et al. (10) recently 
demonstrated that the type of intestinal inflammation, normal 
vs acute or chronic inflammation, is associated with the profile 
of mucosal microbiota in patients with SpA. In particular, in 
the inflamed biopsy tissues the bacterial community composi-
tion was completely different compared with non-inflamed 
biopsy tissues. The authors also found that the abundance of the 
Dialister genus was correlated with the Ankylosing Spondylitis 
Disease Activity score.
ROLe OF DYSBiOSiS in MODiFYinG GUT 
PeRMeABiLiTY in AS
In healthy subjects, the intestinal microbiota cannot access the 
peripheral tissues and/or the systemic circulation avoiding the 
induction of systemic immune responses. Such compartmentali-
zation is guaranteed by the presence of an epithelial gut barrier 
(11, 12) and of a GVB (13) controlling the translocation of anti-
gens into the blood stream at the same time prohibiting the trans-
location of bacteria and/or bacterial products. The gut-epithelial 
barrier is constituted by a complex system of protein–protein 
networks linking the contiguous cells and closing the intercellular 
space (12). The network of protein that connects epithelial cells 
includes desmosomes, adherens junctions, and tight junctions 
(12). Recently, Spadoni et  al. show that enteroglial cells and 
pericytes are in close contact with intestinal vascular endothelial 
cells and are an integral part of a GVB highly resembling the 
blood–brain barrier (BBB) (13). Like the BBB, endothelial cells 
in the GVB develop tight junctions allowing the diffusion of 
molecules as large as 4 kD, eight times the maximal size observed 
for the BBB. Gut-epithelial barrier and GVB were recently studied 
in the gut of SpA patients by Ciccia et al. (3). In this study, the 
presence of adherent and invading bacteria was associated with a 
profound downregulation of the tight junction proteins claudin 4 
and occludin. The downregulation of tight junction proteins was 
associated in SpA with the upregulation of zonulin, the protein 
that has been demonstrated to modulate the permeability of 
tight junctions between intestinal epithelial cells (14) (Figure 1). 
Zonulin expression in SpA was inversely correlated with claudin 
1, claudin 4, occludin, and zonula occludens and modulated by 
intestinal bacteria as demonstrated by the evidence that isolated 
ileal bacteria from patients with SpA induced a significant 
upregulation of zonulin on Caco-2 cells (3). The altered intestinal 
epithelial permeability was accompanied by the alteration of the 
GVB in SpA patients (Figure 1). VE cadherin, the most relevant 
endothelial adhesion molecule, and JAM-A, a vascular tight 
junctions protein, were significantly downregulated in the gut of 
patients with SpA together with the upregulation of PV1, a marker 
of endothelial cells permeability, especially in those patients with 
chronic gut inflammation (3). Confocal microscopy analysis 
of SpA ileal samples showed the disappearance of the classic 
endothelial continuous staining of CD31, a marker of endothelial 
cells and of glial fibrillar acid protein a marker of glial cells, con-
firming the disorganization of GVB (3). Alterations of epithelial 
and endothelial layers permeability, was associated with increased 
serum levels of lipopolysaccharide (LPS), LPS-BP and intestinal 
fatty acid binding protein. The presence of high LPS concentra-
tion was associated in SpA with the significant downregulation 
of the CD14, the co-receptor for LPS, expression on circulating 
monocytes (3). The findings coming from this study do not allow 
clarifying whether or not the intestinal bacteria might induce 
these alterations. However, HLA-B27 rats display ileal inflam-
mation characterized by the downregulation of occludin and the 
presence of adherent bacteria (3). Antibiotics treatment caused 
the normalization of occludin expression and the disappearance 
of adherent bacteria suggesting a role of intestinal microbiome in 
modulating the integrity of epithelial barrier (3).
4Rizzo et al. Gut Inflammation in SpA
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DYSBiOSiS MAY MODULATe iL-23 
PRODUCTiOn in AS GUT
The inflamed gut of SpA patients has been demonstrated to be 
the main site where the production of IL-23 takes place (15). The 
demonstration that in HLA-B27 transgenic rats the antibiotics 
treatment induces the normalization of IL-23 expression might 
suggest a role of dysbiosis in the modulation of IL-23 produc-
tion (3). The regulation of IL-23 in SpA gut is, however, not 
completely understood and different pathways of innate immune 
system might be implicated in IL-23 modulation. Autophagy is 
one of these innate immune system pathways targeting intracel-
lular bacteria, in the process termed xenophagy, for lysosomal 
degradation (16). Autophagy is significantly modulated in the 
gut of AS patients with a strong upregulation of autophagy 
related 16-like 1 (ATG16L1), immunity-related GTPase family 
(IRGM) and microtubule-associated proteins 1A/1B light chain 
3A (17). These alterations were more profoundly observed in 
patients with more severe gut inflammation and significantly 
correlated with IL-23p19. In this study, the inhibition of both 
autophagy and chaperone mediated autophagy was required, in 
the presence of LPS, to reduce the numbers of IL-23 expressing 
cells and to increase the IL-23p19 mRNA levels in the LPMCs 
(17) (Figure  1). The intestinal activation of autophagy in SpA 
patients seems to be a tissue-specific phenomenon since that it is 
not present in the peripheral blood (18), the synovial tissues (18) 
and the spine (19) of SpA.
iL-23-DePenDenT innATe iMMUne 
ReSPOnSeS in SpA
IL-23 overexpression has been demonstrated to immunologi-
cally characterize the subclinical inflamed gut of SpA patients 
(15). In SpA gut, IL-23 is mainly produced by infiltrating 
myeloid cells and by a subset of highly specialized epithelial 
cells, located at the base of crypts, the so-called Paneth cells (15). 
IL-23 production has been proved to constitutively occur in the 
terminal ileum of normal subjects (20), suggesting a homeo-
static role of this cytokine in the modulation of gut immune 
responses. In the gut of SpA patients, differently from the gut of 
PsA (21) and Behcet’s disease (22) patients, IL-23 polarization 
seems to be not accompanied by the presence of a clear Th17 
polarization (15), possibly as the results of the occurrence of 
a strong Treg response (23). IL-23, however, is able by itself to 
induce intestinal inflammation (24) and may also induce the 
expansion and activation of different subsets of innate immune 
cells such as innate lymphoid cells type 3 (25, 26), γδ T cells (27), 
and mucosal-associated invariant T cells (28) (Figure 1).
Mucosal-associated invariant T cells are a subset of T lympho-
cytes characterized by the expression of a semi-invariant T cell 
receptor alpha (TCRα) chain (29). The TCRα arises from the 
rearrangement of the variable (V) and joining (J) TCRα segments 
during VDJ recombination. MR1, an MHC class I-like protein, 
is required for the presentation of bacterial-derived vitamin 
B metabolites to MAIT  cells modulating the release of several 
pro-inflammatory cytokines and the ability of killing bacterially 
infected cells. In mice, MAIT cells are activated by IL-23 and IL-1b 
in the absence of TCR stimulation (30). In humans, both IL-7 
and IL-23 are able to induce MAIT cells polarization resulting in 
a different modulation of STAT3, HIF1alpha and RORc (31). IL-7 
stimulation induces in fact a significant STAT3 and HIF1alpha 
upregulation with any relevant modulation of RORc. Conversely, 
IL-23 stimulation significantly induced RORc overexpression not 
affecting STAT3 and/or HIF1alpha expression (31). MAIT cells’ 
development and activation mainly occur in the gut and the 
presence of gut inflammation in a significant percentage of 
SpA patients may strengthen the existence of a gut–joint axis of 
inflammation in AS. Although no data are available regarding 
MAIT  cells frequency and function in SpA gut, the frequency 
of MAIT  cells is reduced in the blood of SpA patients (28). 
Furthermore, patients with SpA have an increased frequency 
IL-17A+ MAIT cells and IL-17+ MAIT cells are enriched in SpA 
synovial fluids (28). However, IL-17 production in SpA periph-
eral MAIT cells seems to be dependent by IL-7 but not IL-23 or 
antigen stimulation (28).
Gamma delta T cells are a subset of T cells in which the genetic 
composition of TCR is encoded by the gamma and delta gene loci, 
enriched in epithelial cell-rich compartments such as the diges-
tive tract (32). Subsets of γδ T cells are differentiated on the basis 
of the inclusion of invariant TCR V-(D)-J segments showing tis-
sue or context specificity. γδ T cells represent a fundamental link 
between adaptive and innate immune responses. They may in fact 
undergo to V-(D)-J segment rearrangement inducing adaptive, 
antigen-specific responses. However, they can also be directly 
activated via the recognition of pathogen-associated molecular 
patterns (PAMPs) or danger-associated molecular patterns, by the 
gamma delta TCR or non-TCR proteins. Like T helper cells, γδ 
T cells produce different effector pro-inflammatory cytokines in 
a subtype and context-specific way. Recently, cocultures of naive 
Vγ9Vδ2 T cells with phosphor antigens and pro-inflammatory 
cytokines, such as IL-1-β, TGF-β, IL-6, and IL-23, have been 
demonstrated to potently induce the polarization toward IL-17 
production by expressing the transcription factor RORγt (33). In 
a murine model of SpA, activated Vγ6+CD27− γ/δ T cells were 
expanded in non-inflamed entheseal tissues representing the 
large majority of RORγt+IL-23R+ entheseal-resident lymphocytes 
(34). In the presence of inflammations, the numbers of γ/δ T cells 
increased in the Achilles tendon enthesis, aortic root, and near 
to the ciliary body (34). In SpA patients, an increased frequency 
of circulating IL-17+IL-23R+ γ/δ T  cells has been also recently 
demonstrated (27). In this study, the frequency of circulating 
IL-23R+ T  cells was twofold higher in SpA patients, being γ/δ 
T  cells the most relevant IL-23R+ population observed in SpA 
patients. The increased expression of IL-23R on γ/δ T cells was 
associated with an augmented IL-17 secretion. Interestingly, no 
observable IL-17 production was found among IL-23R-negative 
γ/δ T cells in SpA. Furthermore, stimulation of γ/δ T cells from 
SpA patients with IL-23 and/or anti-CD3/CD28 strongly induced 
a skewed polarization toward IL-17 production.
ILCs are specialized effector cells characterized by the 
absence of recombined antigen-specific receptors, the absence 
of specific markers associated with other immune cell lineages 
and a lymphoid morphology (35). ILCs have been involved in 
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the innate immunity and inflammation regulation through the 
secretion of specific cytokines and chemokines. Like effector 
T cells, ILCs are divided into three main groups [ILC1, ILC2, 
and innate lymphoid cells of group 3 (ILC3)] based on the 
expression of specific transcription factors and cytokine pro-
duction. ILC1, similar to Th1  cells, express the transcription 
factor Tbet and produce high amount of IFN-γ. Like Th2 cells, 
ILC2 produce IL-5 and IL-13 and are involved in allergy and 
mucosal homeostatic responses. ILC3, expressing the retinoic 
acid-ROR-γ and/or Tbet, are an important source of IL-22 
and IL-17. ILC3 are IL-23-responsive immune cells and play 
a pro-inflammatory role also mediating protective responses 
against extracellular bacterial infections and providing help 
to marginal zone B  cells through the production of BAFF. 
ILC3 depend on IL-7 for their differentiation and are essen-
tially mucosal-restricted cells (36). In the gut of AS patients, 
ILC3 expressing the natural cytotoxicity receptor NKp44 are 
expanded and are characterized by the intense production of 
IL-17 and IL-22. NKp44+ ILC3 (defined as Lyn−IL-23R+NKp44+
Tbet+RORc− cells) are expanded in the gut of patients with SpA 
and were significantly correlated with the disease activity (26). 
ILC3 are developmentally related to lymphoid tissue inducer 
(LTi) cells (37). It has been demonstrated that aggregates of 
LTi cells, the so-called cryptopatches, found in the intestinal 
lamina propria, are the structure responsible for the maturation 
of ILC3 in response to the gut microbiota (38). Interestingly, the 
presence of LTi aggregates, highly resembling for cryptopatches, 
have been recently found in the small intestine of patients with 
SpA in close proximity to intestinal crypts and Paneth cells 
(26). In the gut of SpA, Paneth cells have been demonstrated 
to produce IL-7 and the coculture of LTi with isolated epithe-
lial cells strongly induces the differentiation of ILC3 and the 
expression of IL-17 and IL-22 (26). These results may suggest a 
fundamental role of intestinal dysbiosis in activating intestinal 
innate immune responses in the gut of SpA patients, finally 
resulting in the differentiation and activation of ILC3.
Despite their mucosal restriction, ILC3 were also expanded in 
the peripheral blood, synovial fluids and the bone marrow (BM) 
tissues of SpA patients (26). Interestingly, the majority of these 
cells express the intestinal homing integrin α4β7. According to 
the α4β7 increased expression, the α4β7 ligand MAdCAM1, was 
highly represented in the context of SpA intestinal and BM high 
endothelial venules (26). More recently, ILC3 have been specifi-
cally studied in human enthesis (39). The proportion of ILC3 in 
human entheseal tissue was higher than that in peripheral blood 
and entheseal tissue had a higher proportion of NKp44+ ILC3s. 
Altogether these findings may support the idea that a gut–spine 
axis occur in SpA patients suggesting a role for MAdCAM1 in 
attracting ILC3 in the site of active AS inflammation and the 
recirculation of ILC3 between the gut and the inflamed spine. 
This concept seems to be supported by the findings that a4b7 
block by natalizumab may be effective in ameliorating signs and 
symptoms in SpA patients (40).
It is interesting to note that blocking of IL-23 seems to be less 
effective in patients with SpA and pure axial disease compared 
with patients with peripheral disease (41). Since the evidences 
that blocking IL-17 significantly modifies the progression of axial 
disease in SpA patients we can assume that IL-22 and IL-17 are 
the key cytokines involved in the pathogenesis of AS.
COnCLUSiOn
Spondyloarthritis subclinical gut inflammation may be consid-
ered the occult engine of the disease. In the gut, the complex 
interactions between the microbiome and the host immune 
system may lead to the alteration of intestinal barriers and to 
the aberrant activation of innate immune cells. Recirculating 
innate immune cells from the gut to the extraintestinal sites 
of inflammation may be responsible for the induction of chro nic 
inflammatory responses in patients with SpA.
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